drugset / Trial / NCT00896246

Scintigraphic Assessment Following Klean-Prep® or Moviprep®

NCT00896246

Phase 1 Completed 32 enrolled Norgine
RandomizedParallel-groupOpen-labelTreatment

Summary

This was a phase 1, open-label, randomized study, designed to assess the impact of Moviprep® or Klean-Prep® on gastrointestinal transit. It was performed in two parallel groups with Part A in two groups of four subjects preceding Part B, which was performed in two groups of 12 subjects. Subjects attended a pre-study medical within 28 days of dosing and a post-study medical 5-10 days after the final dose. Within both Part A and Part B, subjects were required to attend the clinical unit for 2 study periods. Part A consisted of a baseline period to determine individual reference times for gastrointestinal transit. Part B was the test period in which gastrointestinal transit following the administration of the test preparations was assessed.

Timeline

Start
2006-09
Primary completion
2006-10
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Klean-Prep® Other / unclassified 4000 ml Oral
Subject Moviprep Other / unclassified 2000 ml Oral

Indications

No indication recorded.